

## REMARKS

### I. Amendments

By this amendment, new claims 8-24 have been added and claims 1-7 have been cancelled.

This amendment adds no new matter to the specification. Support for this amendment is found in the specification as indicated below:

- independent method claims 8, 12 and 16 at page 6, lines 13-20 and page 6, line 31 – page 7, line 28
- claims 9, 13 and 22 at page 1, lines 20-27
- claims 10, 14 and 23 at page 23, Table 2
- claims 11, 15 and 24 at page 24, Table 3
- claim 17 at page 11, lines 29-30
- claim 18 at page 12, lines 15-23
- claims 19-21 at page 11, line 31- page 12, line 14.

In addition, minor typographical and grammatical corrections to the specification.

No amendment of inventorship is necessitated by this amendment.

II. Conclusion

Consideration of the pending claims as amended is solicited. Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants' attorney.

Respectfully submitted,

Dated: September 4, 2003

Elaine M. Ramesh

(847) 383-3391

(847) 383-3372

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Mark Chao, Ph.D., Reg. No. 37,293

Attorney for Applicants

Customer No. 23,115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
Suite 500, 475 Half Day Road  
Lincolnshire, IL 60069 USA

**Certificate of Mailing under 37 CFR 1.10**

The undersigned hereby certifies that this document, along with any attachments, is being deposited in an envelope addressed to The Commissioner of Patents and Trademarks, with sufficient postage with the United States Postal Service EXPRESS MAIL Post Office to Addressee Service on this date September 4, 2003.

Express Mail Label No. EV 310941899 US

Gail L. Winokur

Printed Name: Gail L. Winokur